GLP1R and breast cancer: GLP 1 receptor agonists decreased the risk of developing cancer-related lymphedema in patients following axillary lymph node dissection for BC [81,82] and reduced the risk of basal cell carcinoma and BC but augmented the risk of colorectal cancer [83].